Camurus to present at Jefferies 2017 London Healthcare Conference
Lund, Sweden — 7 November 2017 — Camurus (Nasdaq Stockholm; CAMX) today announced that the Company will present at Jefferies 2017 London Healthcare Conference 16 November at 3:20 pm local time (GMT). Fredrik Tiberg, President and CEO, will update on the progress of the development pipeline, including the ongoing registration processes of CAM2038 weekly and monthly depots of buprenorphine developed for treatment of opioid dependence.
A webcast of the presentation can be accessed live via Camurus website www.camurus.com .
Camurus is a Swedish research-based pharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the proprietary FluidCrystal® drug delivery technologies and an extensive R&D expertise. Camurus’ clinical pipeline includes products for treatment of cancer, endocrine diseases, pain and addiction, developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker “CAMX”. For more information, visit www.camurus.com .
For more information
Fredrik Tiberg, President & CEO
Tel. +46 (0)46 286 46 92
Rein Piir, VP Investor Relations
Tel. +46 (0)70 853 72 92
The information was submitted for publication at 8.00 pm CET on 7 November 2017.